Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PRX-105

Other · developed by Protalix

Early Phase 1 Most advanced trial (none active)
PLX Developer
1 Registered trials

What is PRX-105?

PRX-105 is an investigational drug studied in Organophosphate Exposure.

At a glance

Drug type
Other
Developer
Protalix (PLX)
FDA status
Investigational, not approved in the US. Most advanced trial: Early Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01093859 Early Phase 1 Organophosphate Exposure Completed PLX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Organophosphate Exposure

More from Protalix

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PLX page.

Follow PLX, the company behind PRX-105

See PLX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PLX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.